For the second year in a row, flashes of pink cut through the sea of navy, gray and black that flooded San Francisco’s Union ...

The five-year results come from a phase 2b study that tested intismeran autogene in combination with Merck’s Keytruda in ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

The global, double-blinded phase 3 study enrolled 165 patients aged between 12 and 75 years and measured the time to onset ...

Worldwide Clinical Trials is expanding its horizons with the acquisition of Catalyst Clinical Research, a specialist oncology ...

Microsoft and Bristol Myers Squibb have signed a new pact aimed at identifying lung cancer cases more quickly. | Microsoft ...

Two former executives from Spero Therapeutics have agreed to settle with the Securities and Exchange Commission for allege | ...

Abbott is teaming up with AtaCor Medical to develop a next-generation implantable cardioverter defibrillator (ICD) designed ...

Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...

Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...

AstraZeneca had already bagged the rights to the AbelZeta Pharma-partnered CAR-T cell therapy for most of the world. | The ...